ClinicalTrials.gg
Status unknownNCT04405505Updated May 28, 2020

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

A Phase 3 interventional study of TQB2450 and Anlotinib in Triple Negative Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
46th of 235
332 · median 90
Started
2020
with 20 others
Phase 3
48 of 252
19 open now
Registered
68th of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 46th largest by planned enrollment of the 235 interventional ones that give a count, is one of 21 that started in 2020, is one of 48 in phase 3, and was the 68th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. (ECOG) performance status of 0 to 1; ≥ 3 months.

    2. confirmed triple negative breast cancer. 3.Has at least one . 4.Newly diagnosed stage IV or recurrent/ triple negative breast cancer who are not suitable for surgery.

    5.Prior local radiotherapy for metastatic sites is allowed. 6.Adequate laboratory indicators. 7.Understood and signed an form. 8.No pregnant or breastfeeding women, and a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • 1.Has received anti-angiogenic drugs or other / PD-L1 / CTLA-4 antibody therapy or other immunotherapy against PD-1 / PD-L1 / CTLA-4.

    1. Severe occurs after administration of other monoclonal antibodies.
    1. Has other (except cured skin basal cell carcinoma and cervical carcinoma in situ) within 3 years.
    1. Has any active disease or history of autoimmune disease. 5. Has a clear clinical diagnosis of interstitial pneumonia, pulmonary fibrosis, drug-induced pneumonia, or active pneumonia.
    1. Peripheral neuropathy ≥ grade 2. 7. or systemic or absorbable local hormone therapy is required to achieve the aim of immunosuppression (dose > 10mg/ day prednisone or other therapeutic hormones) and is still used within 2 weeks after the first administration.
    1. Has multiple factors affecting oral medication. 9. Has uncontrolled and repeated drainage pleural effusion, pericardial effusion, and ascites.
    1. Has any signs of bleeding or history. 11. Has unrelieved spinal cord compression. 12. Has symptomatic central nervous system (CNS) disease and / or cancerous meningitis, pia mater disease.
    1. Has received other anti-tumor therapy within 4 weeks before the first administration.
    1. Has any serious and/or uncontrollable disease. 15. Has received vaccination or attenuated vaccine within 4 weeks before the first administration.
    1. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    TQB2450 + Anlotinib

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 · Drug: Anlotinib

  • Active comparator
    Paclitaxel for injection (albumin bound)

    Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.

    Drug: Paclitaxel for Injection (albumin bound)

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • a multi-target receptor tyrosine kinase inhibitor.

  • a anti-microtubule drug.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) evaluated by Independent Review Committee(IRC)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.

    Time frame: up to 96 weeks

Secondary outcomes

  1. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 96 weeks

  2. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  3. Duration of Response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

    Time frame: up to 96 weeks

07

Study locations

30 sites
  • The Fourth Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    • Yunhong Xia, Doctor · Contactyhxia@sina.com
    • Yunhong Xia, Doctor · Principal investigator
  • Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    • Hongyan Ying, Doctor · Contactyinghy15@163.com
    • Hongyan Ying, Doctor · Principal investigator
  • Beijing Shijitan Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100038, China
    • Jun Ren, Doctor · Contactjun.ren@duke.edu
    • Jun Ren, Doctor · Principal investigator
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing 102218, China
  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 400000, China
    • Xiaohua Zeng, Doctor · Contact1340110079@qq.com
    • Xiaohua Zeng, Doctor · Principal investigator
  • The First Affilited Hospital of Chongqing Medical University
    Chongqing, Chongqing 400042, China
    • Lu Gan, Doctor · Contactganlu99@sina.com
    • Lu Gan, Doctor · Principal investigator
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510030, China
    • Ning Liao, Doctor · Contactdrningliao@163.com
    • Ning Liao, Doctor · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi Zhuang Autonomous Region 530021, China
    • Wenxian Zhou, Doctor · Contact939935994@qq.com
    • Wenxian Zhou, Doctor · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi Zhuang Autonomous Region 530021, China
    • Jincai Zhong, Master · Contact
    • Jincai Zhong, Master · Principal investigator
  • The fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050010, China
  • Affiliated Tumor Hospital of Harbin Medical University
    Harbin, Heilongjiang 150000, China
    • Qingyuan Zhang, Doctor · Contactsy86298276@163.com
    • Qingyuan Zhang, Doctor · Principal investigator
  • AnYang Tumor Hospital
    Anyang, Henan 455000, China
    • Jing Sun · Contact
    • Jing Sun · Principal investigator
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430061, China
    • Yahua Zhong, Doctor · Contactdoctorzyh73@163.com
    • Yahua Zhong, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    • Quchang Ouyang, Doctor · Contactoyqc1969@126.com
    • Quchang Ouyang, Doctor · Principal investigator
  • Nantong Tumor Hospital
    Nantong, Jiangsu 226000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    • Wei Li, Doctor · Contactjdyylw@163.com
    • Wei Li, Doctor · Principal investigator
  • Yanbian University Hospital
    Yanji, Jilin 133000, China
    • Songnan Zhang, Doctor · Contactzhangsn21@163.com
    • Songnan Zhang, Doctor · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110011, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
    • Tao Sun, Doctor · Contactlnzlrxnsy@163.com
    • Tao Sun, Doctor · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030013, China
    • Fuguo Tian, Master · Contact2205473988@qq.com
    • Fuguo Tian, Master · Principal investigator
  • The Second Affiliated Hospital of PLA Airforce Military Medical University
    Xi'an, Shanxi 710032, China
    • Huadong Zhao, Doctor · Contactzhaolujy@fmmu.edu.cn
    • Huadong Zhao, Doctor · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
    • Yu Ren, Doctor · Contactrenyyyyy@126.com
    • Yu Ren, Doctor · Principal investigator
  • Shanxi Provincial People's Hospital
    Xi'an, Shanxi 710068, China
  • The Second People's Hospital of Neijiang
    Neijiang, Sichuan 641100, China
    • Xujuan Wang, Master · Contact61132803@qq.com
    • Xujuan Wang, Master · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
    • Zhongsheng Tong · Contact
    • Zhongsheng Tong · Principal investigator
  • Xinjiang Uiger Municipal People's Hospital
    Urumqi, Xinjiang 830000, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    • Xiaojia Wang, Doctor · Contactwxiaojia0803@163.com
    • Xiaojia Wang, Doctor · Principal investigator
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2020; primary completion for Jul 2022, 25 months later.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2020
First posted
May 28, 2020
StartEst.
Jun 1, 2020
Primary completionEst.
Jul 1, 2022
CompletionEst.
Jul 1, 2022
Last update
May 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04405505
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Jun 1, 2020 (estimated)
Primary completion
Jul 1, 2022 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
May 28, 2020

Study contacts

Binghe Xu, Doctor
Contact
xubinghe@medmail.com.cn
010-87788826

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benmelstobart

Start the discussion